SlideShare a Scribd company logo
1 of 44
Download to read offline
EXPERTS WORKSHOP ON EARLY TREATMENT  STRATEGIES FOR ACUTE MYOCARDIAL INFARCTION FOR THE MIDDLE EAST COUNTRIES FEBRUARY 26 TH  -28 TH  2005 / DUBAI, UAE SPONSORED BY BOEHRINGER INGELHEIM SUNDAY, 27 th  FEBRUARY – SESSION 2 A rationale for pre-hospital thrombolytic therapy Patrick Goldstein
Fire ! ,[object Object]
The Fire Spreads Quickly ,[object Object]
Transportation !? ,[object Object]
To  Extinguish the Fire ! ,[object Object]
“ Time is Muscle”  Cross-sections of left ventricle after experimental coronary artery occlusion (Reimer KA, et al. Circulation. 1977;56:786-794). Duration of occlusion 3 h Area supplied by occluded artery x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x XXXX Necrosis Ischemic but viable Non-ischemic 24 h 40 min
Acute MI again? Why? ,[object Object],[object Object],[object Object],[object Object],[object Object]
“ Time is muscle”   MITI 4.9 11.2 14 12 10 8 6 4 2 0 Infarct Size (%) < 70 min 70-180 min
Estimated benefit (lives saved at 35 days) per 1000 patients Time  from onset (hours) Mortality Reduction Depends on the Delay  “Onset of Pain - Thrombolytic Treatment” Eric Boersma’s meta-analysis (22 trials  from  83 to 93 - 50 246 patients) BOERSMA, E. et al Early thrombolytic in acute myocardial treatment infarction : reappraisal of the golden hour - Lancet 1996 ; 771 - 775 0 12 18 24 6 0 20 40 60 80 11% 30 to  50 lives saved  for 1000 patients 1 to 3  hours 60 to 80  lives saved for 1000 patients 30 to 60 min 1- month benefit Delay
Morrison’s Meta-analysis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],JAMA, May 2000 - Vol 283 - N °  20 - 2686-92
Delay pain – treatment French experience 1.60 1.59 2.10 2.10 2.35 3.03 3.03 2.50 3.03 2002 2001 1997 2001 2002 2001 2000 1995 1990 ESTIM Nord ESTIM IdF STIM SAMU CAPTIM A3+ A3 A2 G3 GI
Material and Drugs of   the  SMUR  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ASSENT-3  Plus (Pre-hospital Treatment) Early treatment  (ambulance-car) of AMI patients <6 hrs  ASA RANDOMIZATION  1:1 TNK-tPA full dose 0.53 mg/kg bolus Unfractionated heparin   60 IU/kg bolus (max. 4000  IU) 12 IU/kg/hr infusion (max 1000 IU/ hr) target aPTT 50-70 sec Patients’ outcome  will be compared with matched pairs extracted from the corresponding arm of the ASSENT-3 main study. The same exploratory endpoints (single and composite) as in the ASSENT-3 main study will be evaluated; the influence of  time to treatment  will be analyzed. (500) TNK-tPA full dose  0.53 mg/kg bolus Enoxaparin  30 mg i.v. bolus 1 mg/kg s.c. twice a day  (500)
Hours to treatment  (median) 3+ 0 12 24 36 48 60 72 84 96 108 120 132 144 156 168 ENOX UFH TNK TNK Symptom - call Call - arrival Arrival - Rand. Rand. - first drug First drug - ER ASSENT-3 In-hospital Symptom – TNK 45 min
Thrombolysis or PTCA still a debate ?
CAPTIM ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],ESC 2001
[object Object],CAPTIM  Design ST segment     onset of pain < 6 h All received ASA + Heparin Central randomisation In-hospital  Pre-hospital PCI   thrombolysis Diagnosis positive in 95%
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],CAPTIM - Clinical Endpoints
[object Object],[object Object],[object Object],[object Object],CAPTIM - Results primary endpoint Pre-hospital thrombolysis  n = 419 Primary PCI n = 421 P  Value 8.2 RR = 0.76 3.8 3.7 1.0 6.2 RR = 0.76 4.8 1.7 0.0 0.29 0.60 0.13 0.12
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],CAPTIM - secondary endpoints Pre-hospital thrombolysis  n = 419 Primary PCI n = 421 P  Value 3.8 7.2 33.0 2.5 0.5 0.5 4.3 4.0 4.0 4.9 0.0 2.0 0.86 0.09 < 0.01 0.09 0.49 0.06
DANAMI-2 DENMARK 5.4 mill. inhabitants 5 PCI centers 24 referral hospitals 62% of Danish  population Transport distance up to 95 US miles  (mean 35 miles) 100 US miles
DANAMI II ACC 2002 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Very high risk patients: ST > 4 mm
Comparaison CAPTIM / DANAMI II ,[object Object],[object Object],[object Object],[object Object],[object Object],Combined Death, ReMI and stroke
[object Object],[object Object],[object Object],[object Object],[object Object],Look at the  single  endpoints:  30 days
Preventing Reinfarction :  IIb/IIIa Inhibitors, Enoxaparin, or Primary PCI PRAGUE-2 30-day deaths 6.8 v 10.0 % , p = 0.12 *  6-month data in press,  Simes AHU 2002 ** Pre-hospital administration p < 0.05 reMI, death (PCAT only) ; stroke (PCAT only) CAPTIM 840 PCI  t - PA** DANAMI - 2 1.572 PCI  t - PA C - PORT* 451 PCI  t - PA PCAT* 2.725 PCI  lytic Death 4.6% 3.7% 6.6% 7.6% 6.2% 7.1% 6.2% 8.2% ReMI 1.7% 3.7% 1.6% 6.3% 5.3% 10.6%  4.8% 9.8% Stoke 0 1.0% 1.1% 2.0% 2.2% 4.0% 0.7% 1.9%
DANAMI-2 vs CAPTIM vs ASSENT-3 Mortality at 30 days % (TNK + ENOX) ESSAI TOTAL 6.6 4.8 7.6 3.8 5.4 5.8 0 2 4 6 8 DANAMI-2 CAPTIM ASSENT-3 ASSENT3+ PCI TT
CAPTIM 1-Year Results Pre-Hospital Lysis Primary PCI Death GW Symposium, AHA 2002 Death Pre-Hospital Lysis Primary PCI Sx < 2 hours Sx  >  2 hours P=0.057 P=0.47 2.2% 5.7% 0% 5% 5.9% 3.7% 0% 10%
CAPTIM 1 Year Results Pre-Hospital Lysis Primary PCI P=0.032 Shock Randomization to DC GW Symposium, AHA 2002 P=0.0007 Shock Randomization to Adm Pre-Hospital Lysis Primary PCI Sx < 2 hours Sx < 2 hours 1.3% 5.3% 0% 5% 0.0% 3.6% 0%
All presented periods are median Beginning  of pain 65 min Emergency  call at  SAMU 19 min PEC SMUR Beginning  of thrombolysis 35 min 66 min Arrival at hospital 84 min Puncture According to ATLS: 32 min 120 min 185 min E-MUST Comparable  periods
 
The Lille Experience 4h55 3h 3h 1h49 1h42 0 1 2 3 4 5 6 Thr. pre-hosp. Thr. pre-hosp. + angioplasty Thr. hosp. Thr. hosp.+ angioplasty Angioplasty
USIC 2000 ,[object Object],[object Object],[object Object],[object Object],[object Object]
One-month Mortality in Patients  with Reperfusion Therapy:  USIC 2000 n = 428   370   108   47 %   41 %   12 % 7.9 7.8 4.6 0 1 2 3 4 5 6 7 8 9 Primary PTCA IV lysis Lysis + PTCA
USIC 2000: One-month Mortality  in Patients with Reperfusion Therapy n = 370   108   428   41%   12%   47% 7.1 9.6 3.0 5.8 3.6 7.9 0 2 4 6 8 10 12 Hosp. lysis no PCI Pre-hosp. lysis no PCI Hosp. lysis + PCI Pre-hosp. lysis + PCI Primary PCI
Combined Strategy of reperfusion
The Combined Strategies of Reperfusion   J.M. Julliard :  A matched comparison of the combination of prehospital thrombolysis  and stand bye rescue angioplasty with primary angioplasty. Am.J. Cardiol. 1999 ; 83 - 305-310. 170 patients in Paris city Pre-hospital Thrombolysis Angiography at 80 min TIMI 3 108 (64%) TIMI 2 12 (7%) TIMI 0 50 (29%) angioplasty TIMI 3 91% TIMI 2 7%
Which Delays for This Technique of Combined Reperfusion ,[object Object],[object Object],[object Object],2 h after PHT only 2% of patients are TIMI O or 1
[object Object],1995-1999 1010 patients  with AMI (Paris Sud Cardiovascular Institute) 148 patients  with pre-hospital full-dose thrombolytic therapy 131 patients included (median time = 2 h after onset of pain ) C. Loubeyre and all. Eur. Heart J. 2001 ; 22 : 1128-1135
131 patients Angiography 95 min after TT 64 (49%) TIMI 3 54 (84%) PTCA  65 (50%) TIMI 0 - 2 PTCA  119 (91%) PTCA 114 stent 120/131  TIMI 3 (92%) 9/131  TIMI 2 2  TIMI 0-1 no emergency surgery From C. Loubeyre
Long-term follow-up  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],C. Loubeyre. Eur. Heart J. 2001 ; 22 : 1128-1135
Early PCI versus Guided PCI  after Lytics in the Modern Era   Death Relative risk, fixed model Bilateral CI, 95% for trials, 95% for MA SIAM III 0.44  [0.14;1.37] GRACIA-1 0.57  [0.26;1.26] CAPITAL-AMI 0.67  [0.11;3.89] Total 0.54  [0.29;0.99]  0.047 Cochran Q het. p=0.91 Rel. Risk 0 1 2 3 4 0.538, p=0.047 RR  CI  p
Rescue PCI after Lytics RESCUE 0.53  [0.16;1.75] REACT 0.51  [0.24;1.10] MERLIN 1.14  [0.59;2.20] LIMI 0.84  [0.27;2.65] Belenkie et al 0.19  [0.02;1.47] Total 0.73  [0.48;1.11]  0.138 Cochran Q het. P=0.33 Death 6 weeks Relative risk, fixed model Bilateral CI, 95% for trials, 95% for MA Rel. Risk 0.4 1.0 1.6 2.2 RR  CI  p
Conclusion ,[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],EP. Mc Fadden. Eur. Heart J. 2001 ; 22 : 1067-69

More Related Content

What's hot

Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...
Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...
Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...Chaichuk Sergiy
 
PCI complications
PCI complicationsPCI complications
PCI complicationsIqbal Dar
 
Role of echocardiography in acute myocardial infraction
Role of echocardiography in acute myocardial infractionRole of echocardiography in acute myocardial infraction
Role of echocardiography in acute myocardial infractionRakesh Kumar Messi
 
acute coronary syndrome (MI)
acute coronary syndrome (MI)acute coronary syndrome (MI)
acute coronary syndrome (MI)Nur Idris
 
TAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENT
TAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENTTAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENT
TAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENTDr Virbhan Balai
 
SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization ...
SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization ...SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization ...
SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization ...vaibhavyawalkar
 
Guiding catheter in coronary intervention
Guiding catheter in coronary interventionGuiding catheter in coronary intervention
Guiding catheter in coronary interventionkefelegn Tadesse
 
Complication and management of rotablation
Complication and management of rotablationComplication and management of rotablation
Complication and management of rotablationNilesh Tawade
 
Coronary anomalies
Coronary anomalies Coronary anomalies
Coronary anomalies hospital
 
Esc 2020 guidelines for the management of acute coronary
Esc 2020 guidelines for the management of acute coronaryEsc 2020 guidelines for the management of acute coronary
Esc 2020 guidelines for the management of acute coronaryHimanshu Rana
 

What's hot (20)

Chronic total occlusion
Chronic total occlusionChronic total occlusion
Chronic total occlusion
 
Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...
Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...
Intraluminal coronary thrombus aspiration in patients with STEMI. Prof. Andre...
 
PTMC/PBMC
PTMC/PBMCPTMC/PBMC
PTMC/PBMC
 
PCI complications
PCI complicationsPCI complications
PCI complications
 
Role of echocardiography in acute myocardial infraction
Role of echocardiography in acute myocardial infractionRole of echocardiography in acute myocardial infraction
Role of echocardiography in acute myocardial infraction
 
Final thrombus burden
Final thrombus burdenFinal thrombus burden
Final thrombus burden
 
CORONARY STENTS.pptx
CORONARY STENTS.pptxCORONARY STENTS.pptx
CORONARY STENTS.pptx
 
State-of-the-Art-Cardiology-Practice: Management OF Acute Coronary Syndrome P...
State-of-the-Art-Cardiology-Practice: Management OF Acute Coronary Syndrome P...State-of-the-Art-Cardiology-Practice: Management OF Acute Coronary Syndrome P...
State-of-the-Art-Cardiology-Practice: Management OF Acute Coronary Syndrome P...
 
acute coronary syndrome (MI)
acute coronary syndrome (MI)acute coronary syndrome (MI)
acute coronary syndrome (MI)
 
TAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENT
TAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENTTAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENT
TAVR/TAVI/TRANCATHETER SAORTIC VALVE REPLECEMENT
 
Stent thrombosis
Stent thrombosisStent thrombosis
Stent thrombosis
 
Chronic total occlusion (CTO)
Chronic total occlusion  (CTO)Chronic total occlusion  (CTO)
Chronic total occlusion (CTO)
 
SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization ...
SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization ...SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization ...
SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization ...
 
Guiding catheter in coronary intervention
Guiding catheter in coronary interventionGuiding catheter in coronary intervention
Guiding catheter in coronary intervention
 
HFPEF
HFPEFHFPEF
HFPEF
 
Complication and management of rotablation
Complication and management of rotablationComplication and management of rotablation
Complication and management of rotablation
 
Coronary anomalies
Coronary anomalies Coronary anomalies
Coronary anomalies
 
Esc 2020 guidelines for the management of acute coronary
Esc 2020 guidelines for the management of acute coronaryEsc 2020 guidelines for the management of acute coronary
Esc 2020 guidelines for the management of acute coronary
 
Ivus
Ivus Ivus
Ivus
 
Courage Trial
Courage TrialCourage Trial
Courage Trial
 

Viewers also liked

Thrombolysis vs PCI for STEMI
Thrombolysis vs PCI for STEMIThrombolysis vs PCI for STEMI
Thrombolysis vs PCI for STEMIJunhao Koh
 
Angiography and Angioplasty
Angiography and AngioplastyAngiography and Angioplasty
Angiography and Angioplastysmithjones1990
 
Localization of MI on ECG
Localization of MI on ECGLocalization of MI on ECG
Localization of MI on ECGNooh Khushal
 
Angioplasty
AngioplastyAngioplasty
Angioplastymattksee
 
Interventiontionist Treatment of Acute DVT
Interventiontionist Treatment of Acute DVTInterventiontionist Treatment of Acute DVT
Interventiontionist Treatment of Acute DVTSalutaria
 
thoracic interventions.ppt
thoracic interventions.pptthoracic interventions.ppt
thoracic interventions.pptsobramid
 
Principles of angioplasty -Endovascular Management of Peripheral Vascular Dis...
Principles of angioplasty -Endovascular Management of Peripheral Vascular Dis...Principles of angioplasty -Endovascular Management of Peripheral Vascular Dis...
Principles of angioplasty -Endovascular Management of Peripheral Vascular Dis...Saurabh Joshi
 
Advances In Varicose Vein Treatment
Advances In Varicose Vein TreatmentAdvances In Varicose Vein Treatment
Advances In Varicose Vein Treatmentguestad3816b5
 
Modern management of dvt dr. sharfuddin chowdhury
Modern management of dvt dr. sharfuddin chowdhuryModern management of dvt dr. sharfuddin chowdhury
Modern management of dvt dr. sharfuddin chowdhuryShakila Rifat
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarctionadolescent4u
 

Viewers also liked (20)

Thrombolysis vs PCI for STEMI
Thrombolysis vs PCI for STEMIThrombolysis vs PCI for STEMI
Thrombolysis vs PCI for STEMI
 
Angioplasty
AngioplastyAngioplasty
Angioplasty
 
Angiography and Angioplasty
Angiography and AngioplastyAngiography and Angioplasty
Angiography and Angioplasty
 
PTCA
PTCAPTCA
PTCA
 
Ptca vs cabg
Ptca vs cabgPtca vs cabg
Ptca vs cabg
 
Localization of MI on ECG
Localization of MI on ECGLocalization of MI on ECG
Localization of MI on ECG
 
Pami Presentation - Cotonou
Pami Presentation - CotonouPami Presentation - Cotonou
Pami Presentation - Cotonou
 
Angioplasty
AngioplastyAngioplasty
Angioplasty
 
Interventiontionist Treatment of Acute DVT
Interventiontionist Treatment of Acute DVTInterventiontionist Treatment of Acute DVT
Interventiontionist Treatment of Acute DVT
 
ELECTROCARDIOGRAM
ELECTROCARDIOGRAMELECTROCARDIOGRAM
ELECTROCARDIOGRAM
 
thoracic interventions.ppt
thoracic interventions.pptthoracic interventions.ppt
thoracic interventions.ppt
 
Iliofemoral DVT thrombolysis
Iliofemoral DVT thrombolysisIliofemoral DVT thrombolysis
Iliofemoral DVT thrombolysis
 
Principles of angioplasty -Endovascular Management of Peripheral Vascular Dis...
Principles of angioplasty -Endovascular Management of Peripheral Vascular Dis...Principles of angioplasty -Endovascular Management of Peripheral Vascular Dis...
Principles of angioplasty -Endovascular Management of Peripheral Vascular Dis...
 
Percutaneous coronary intervention
Percutaneous coronary interventionPercutaneous coronary intervention
Percutaneous coronary intervention
 
Thrombolysis
ThrombolysisThrombolysis
Thrombolysis
 
Advances In Varicose Vein Treatment
Advances In Varicose Vein TreatmentAdvances In Varicose Vein Treatment
Advances In Varicose Vein Treatment
 
CABG VS PCI
CABG VS PCI CABG VS PCI
CABG VS PCI
 
Modern management of dvt dr. sharfuddin chowdhury
Modern management of dvt dr. sharfuddin chowdhuryModern management of dvt dr. sharfuddin chowdhury
Modern management of dvt dr. sharfuddin chowdhury
 
The most important drugs used in dentistry
The most important drugs used in dentistry The most important drugs used in dentistry
The most important drugs used in dentistry
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 

Similar to Primary angioplasty

A magdy when 2 pci after mi
A magdy when 2 pci  after miA magdy when 2 pci  after mi
A magdy when 2 pci after miAhmed Magdy
 
Intervention treatment for acs
Intervention treatment for acsIntervention treatment for acs
Intervention treatment for acsKyaw Win
 
STEMI - Cath Lab
STEMI - Cath LabSTEMI - Cath Lab
STEMI - Cath Labishakansari
 
Primary PCI: State of the art. Petr Widimsky
Primary PCI: State of the art. Petr WidimskyPrimary PCI: State of the art. Petr Widimsky
Primary PCI: State of the art. Petr WidimskyChaichuk Sergiy
 
FIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptxFIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptxdrsbansal2000
 
STEMI – My Approach 2010
STEMI – My Approach 2010STEMI – My Approach 2010
STEMI – My Approach 2010ishakansari
 
Ami Selayang Hospital
Ami Selayang HospitalAmi Selayang Hospital
Ami Selayang HospitalRashidi Ahmad
 
Future of site stable to unstable
Future of site stable to unstableFuture of site stable to unstable
Future of site stable to unstableoptimacardio
 
Acute Stroke Management Handouts Power Point885
Acute Stroke Management Handouts   Power Point885Acute Stroke Management Handouts   Power Point885
Acute Stroke Management Handouts Power Point885MedicineAndHealthNeurolog
 
Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020EkaPratiwi69
 
Role of More Potent Antiplatelet in ACS Management
Role of More Potent Antiplatelet in ACS ManagementRole of More Potent Antiplatelet in ACS Management
Role of More Potent Antiplatelet in ACS ManagementPERKI Pekanbaru
 
Heart Disease & Chest Pain Treatment At NT Cardiovascular Center Georgia
Heart Disease & Chest Pain Treatment At NT Cardiovascular Center GeorgiaHeart Disease & Chest Pain Treatment At NT Cardiovascular Center Georgia
Heart Disease & Chest Pain Treatment At NT Cardiovascular Center Georgiamelvillejackson
 
Enoxaparin Proven Across the ACS Spectrum
Enoxaparin Proven Across the ACS SpectrumEnoxaparin Proven Across the ACS Spectrum
Enoxaparin Proven Across the ACS SpectrumPERKI Pekanbaru
 
Armyda 5
Armyda 5Armyda 5
Armyda 5momiamd
 

Similar to Primary angioplasty (20)

A magdy when 2 pci after mi
A magdy when 2 pci  after miA magdy when 2 pci  after mi
A magdy when 2 pci after mi
 
Intervention treatment for acs
Intervention treatment for acsIntervention treatment for acs
Intervention treatment for acs
 
STEMI - Cath Lab
STEMI - Cath LabSTEMI - Cath Lab
STEMI - Cath Lab
 
Primary PCI: State of the art. Petr Widimsky
Primary PCI: State of the art. Petr WidimskyPrimary PCI: State of the art. Petr Widimsky
Primary PCI: State of the art. Petr Widimsky
 
FIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptxFIBRINOLYTIC THERAPY.pptx
FIBRINOLYTIC THERAPY.pptx
 
STEMI – My Approach 2010
STEMI – My Approach 2010STEMI – My Approach 2010
STEMI – My Approach 2010
 
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
Practice Intersection: How I Approach Thrombus in My Daily Clinical Practice
 
Ami Selayang Hospital
Ami Selayang HospitalAmi Selayang Hospital
Ami Selayang Hospital
 
Future of site stable to unstable
Future of site stable to unstableFuture of site stable to unstable
Future of site stable to unstable
 
Acute Stroke Management Handouts Power Point885
Acute Stroke Management Handouts   Power Point885Acute Stroke Management Handouts   Power Point885
Acute Stroke Management Handouts Power Point885
 
Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020
 
Role of More Potent Antiplatelet in ACS Management
Role of More Potent Antiplatelet in ACS ManagementRole of More Potent Antiplatelet in ACS Management
Role of More Potent Antiplatelet in ACS Management
 
Heart Disease & Chest Pain Treatment At NT Cardiovascular Center Georgia
Heart Disease & Chest Pain Treatment At NT Cardiovascular Center GeorgiaHeart Disease & Chest Pain Treatment At NT Cardiovascular Center Georgia
Heart Disease & Chest Pain Treatment At NT Cardiovascular Center Georgia
 
Triton timi 38
Triton timi 38Triton timi 38
Triton timi 38
 
Enoxaparin Proven Across the ACS Spectrum
Enoxaparin Proven Across the ACS SpectrumEnoxaparin Proven Across the ACS Spectrum
Enoxaparin Proven Across the ACS Spectrum
 
Stroke guidelines
Stroke guidelinesStroke guidelines
Stroke guidelines
 
Cardio Actualidad 2009 - Cardiopatía Isquémica
Cardio Actualidad 2009 - Cardiopatía IsquémicaCardio Actualidad 2009 - Cardiopatía Isquémica
Cardio Actualidad 2009 - Cardiopatía Isquémica
 
09 Cohen aimradial20170922 Ventricular support
09 Cohen aimradial20170922 Ventricular support09 Cohen aimradial20170922 Ventricular support
09 Cohen aimradial20170922 Ventricular support
 
Dr. Wilson
Dr. WilsonDr. Wilson
Dr. Wilson
 
Armyda 5
Armyda 5Armyda 5
Armyda 5
 

More from MedicineAndFamily

Dental Implant Reliability Improvement
Dental Implant Reliability ImprovementDental Implant Reliability Improvement
Dental Implant Reliability ImprovementMedicineAndFamily
 
Nitrous Oxide Sedation in Pediatric Dentistry
Nitrous Oxide Sedation in Pediatric DentistryNitrous Oxide Sedation in Pediatric Dentistry
Nitrous Oxide Sedation in Pediatric DentistryMedicineAndFamily
 
Emergency In Dentistry Part 1
Emergency In Dentistry Part 1Emergency In Dentistry Part 1
Emergency In Dentistry Part 1MedicineAndFamily
 
Evidenced Based Dentistry Spring 2006 Group 4 Kevin Hancock Jess ... Eviden...
Evidenced Based Dentistry Spring 2006 Group 4 Kevin Hancock Jess ... 	 Eviden...Evidenced Based Dentistry Spring 2006 Group 4 Kevin Hancock Jess ... 	 Eviden...
Evidenced Based Dentistry Spring 2006 Group 4 Kevin Hancock Jess ... Eviden...MedicineAndFamily
 
Recent Developments in the Treatment of Hypertension Recent Developments in...
Recent Developments in the Treatment of Hypertension 	 Recent Developments in...Recent Developments in the Treatment of Hypertension 	 Recent Developments in...
Recent Developments in the Treatment of Hypertension Recent Developments in...MedicineAndFamily
 
Subcutaneous emphysema as a complication of tooth extraction Subcutaneous e...
Subcutaneous emphysema as a complication of tooth extraction 	 Subcutaneous e...Subcutaneous emphysema as a complication of tooth extraction 	 Subcutaneous e...
Subcutaneous emphysema as a complication of tooth extraction Subcutaneous e...MedicineAndFamily
 
The Long QT Syndrome: Overview and Management The Long QT Syndrome: Overvie...
The Long QT Syndrome: Overview and Management 	 The Long QT Syndrome: Overvie...The Long QT Syndrome: Overview and Management 	 The Long QT Syndrome: Overvie...
The Long QT Syndrome: Overview and Management The Long QT Syndrome: Overvie...MedicineAndFamily
 
Dental Care of the Future: Part I
Dental Care of the Future: Part IDental Care of the Future: Part I
Dental Care of the Future: Part IMedicineAndFamily
 
Community Dentistry Years I - IV
Community Dentistry Years I - IVCommunity Dentistry Years I - IV
Community Dentistry Years I - IVMedicineAndFamily
 
Preventive Dentistry Lecture Cde Course
Preventive Dentistry Lecture Cde CoursePreventive Dentistry Lecture Cde Course
Preventive Dentistry Lecture Cde CourseMedicineAndFamily
 
Diabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementDiabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementMedicineAndFamily
 
Minimal Intervention Dentistry – The Challenge for Materials
Minimal Intervention Dentistry – The Challenge for MaterialsMinimal Intervention Dentistry – The Challenge for Materials
Minimal Intervention Dentistry – The Challenge for MaterialsMedicineAndFamily
 
ANATOMY of TEETH 2 1. Anatomy of a tooth. a. Anatomical crown ...
ANATOMY of TEETH 2 1. Anatomy of a tooth. a. Anatomical crown ...ANATOMY of TEETH 2 1. Anatomy of a tooth. a. Anatomical crown ...
ANATOMY of TEETH 2 1. Anatomy of a tooth. a. Anatomical crown ...MedicineAndFamily
 
Restorative and Esthetic Dentistry
Restorative and Esthetic DentistryRestorative and Esthetic Dentistry
Restorative and Esthetic DentistryMedicineAndFamily
 

More from MedicineAndFamily (20)

Dental Implant Reliability Improvement
Dental Implant Reliability ImprovementDental Implant Reliability Improvement
Dental Implant Reliability Improvement
 
Dental Radiography Safety
Dental Radiography SafetyDental Radiography Safety
Dental Radiography Safety
 
Nitrous Oxide Sedation in Pediatric Dentistry
Nitrous Oxide Sedation in Pediatric DentistryNitrous Oxide Sedation in Pediatric Dentistry
Nitrous Oxide Sedation in Pediatric Dentistry
 
Emergency In Dentistry Part 1
Emergency In Dentistry Part 1Emergency In Dentistry Part 1
Emergency In Dentistry Part 1
 
Evidenced Based Dentistry Spring 2006 Group 4 Kevin Hancock Jess ... Eviden...
Evidenced Based Dentistry Spring 2006 Group 4 Kevin Hancock Jess ... 	 Eviden...Evidenced Based Dentistry Spring 2006 Group 4 Kevin Hancock Jess ... 	 Eviden...
Evidenced Based Dentistry Spring 2006 Group 4 Kevin Hancock Jess ... Eviden...
 
How to Use Dental Floss
How to Use Dental FlossHow to Use Dental Floss
How to Use Dental Floss
 
Face Eye Trauma
Face Eye TraumaFace Eye Trauma
Face Eye Trauma
 
Dental Caries
Dental CariesDental Caries
Dental Caries
 
Recent Developments in the Treatment of Hypertension Recent Developments in...
Recent Developments in the Treatment of Hypertension 	 Recent Developments in...Recent Developments in the Treatment of Hypertension 	 Recent Developments in...
Recent Developments in the Treatment of Hypertension Recent Developments in...
 
Subcutaneous emphysema as a complication of tooth extraction Subcutaneous e...
Subcutaneous emphysema as a complication of tooth extraction 	 Subcutaneous e...Subcutaneous emphysema as a complication of tooth extraction 	 Subcutaneous e...
Subcutaneous emphysema as a complication of tooth extraction Subcutaneous e...
 
Psychology in Dentistry
Psychology in DentistryPsychology in Dentistry
Psychology in Dentistry
 
The Long QT Syndrome: Overview and Management The Long QT Syndrome: Overvie...
The Long QT Syndrome: Overview and Management 	 The Long QT Syndrome: Overvie...The Long QT Syndrome: Overview and Management 	 The Long QT Syndrome: Overvie...
The Long QT Syndrome: Overview and Management The Long QT Syndrome: Overvie...
 
Dental Care of the Future: Part I
Dental Care of the Future: Part IDental Care of the Future: Part I
Dental Care of the Future: Part I
 
Community Dentistry Years I - IV
Community Dentistry Years I - IVCommunity Dentistry Years I - IV
Community Dentistry Years I - IV
 
Preventive Dentistry Lecture Cde Course
Preventive Dentistry Lecture Cde CoursePreventive Dentistry Lecture Cde Course
Preventive Dentistry Lecture Cde Course
 
Diabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementDiabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental management
 
Minimal Intervention Dentistry – The Challenge for Materials
Minimal Intervention Dentistry – The Challenge for MaterialsMinimal Intervention Dentistry – The Challenge for Materials
Minimal Intervention Dentistry – The Challenge for Materials
 
ANATOMY of TEETH 2 1. Anatomy of a tooth. a. Anatomical crown ...
ANATOMY of TEETH 2 1. Anatomy of a tooth. a. Anatomical crown ...ANATOMY of TEETH 2 1. Anatomy of a tooth. a. Anatomical crown ...
ANATOMY of TEETH 2 1. Anatomy of a tooth. a. Anatomical crown ...
 
Dental Anatomy
Dental AnatomyDental Anatomy
Dental Anatomy
 
Restorative and Esthetic Dentistry
Restorative and Esthetic DentistryRestorative and Esthetic Dentistry
Restorative and Esthetic Dentistry
 

Recently uploaded

The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...JakeMatthews12
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsPradnya Wadekar
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxTina Purnat
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONojaswinihemane
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKQuick MedTalk
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyYves Sucaet
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedSBL DIGITAL
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeQuick MedTalk
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxRajendra Dev Bhatt
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxAbdirahmanWaseem
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUKanhu Charan
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptxtusharchokshi1
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxSizan Thapa
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptxMrStavanUdayKadam
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...DUY NGUYEN PHUC
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhanthesalberry
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdfHongBiThi1
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Ahmad Thanin
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 

Recently uploaded (20)

The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractions
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptx
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathology
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limited
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptx
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptx
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptx
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptx
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhan
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 

Primary angioplasty

  • 1. EXPERTS WORKSHOP ON EARLY TREATMENT STRATEGIES FOR ACUTE MYOCARDIAL INFARCTION FOR THE MIDDLE EAST COUNTRIES FEBRUARY 26 TH -28 TH 2005 / DUBAI, UAE SPONSORED BY BOEHRINGER INGELHEIM SUNDAY, 27 th FEBRUARY – SESSION 2 A rationale for pre-hospital thrombolytic therapy Patrick Goldstein
  • 2.
  • 3.
  • 4.
  • 5.
  • 6. “ Time is Muscle”  Cross-sections of left ventricle after experimental coronary artery occlusion (Reimer KA, et al. Circulation. 1977;56:786-794). Duration of occlusion 3 h Area supplied by occluded artery x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x XXXX Necrosis Ischemic but viable Non-ischemic 24 h 40 min
  • 7.
  • 8. “ Time is muscle” MITI 4.9 11.2 14 12 10 8 6 4 2 0 Infarct Size (%) < 70 min 70-180 min
  • 9. Estimated benefit (lives saved at 35 days) per 1000 patients Time from onset (hours) Mortality Reduction Depends on the Delay “Onset of Pain - Thrombolytic Treatment” Eric Boersma’s meta-analysis (22 trials from 83 to 93 - 50 246 patients) BOERSMA, E. et al Early thrombolytic in acute myocardial treatment infarction : reappraisal of the golden hour - Lancet 1996 ; 771 - 775 0 12 18 24 6 0 20 40 60 80 11% 30 to 50 lives saved for 1000 patients 1 to 3 hours 60 to 80 lives saved for 1000 patients 30 to 60 min 1- month benefit Delay
  • 10.
  • 11. Delay pain – treatment French experience 1.60 1.59 2.10 2.10 2.35 3.03 3.03 2.50 3.03 2002 2001 1997 2001 2002 2001 2000 1995 1990 ESTIM Nord ESTIM IdF STIM SAMU CAPTIM A3+ A3 A2 G3 GI
  • 12.
  • 13. ASSENT-3 Plus (Pre-hospital Treatment) Early treatment (ambulance-car) of AMI patients <6 hrs ASA RANDOMIZATION 1:1 TNK-tPA full dose 0.53 mg/kg bolus Unfractionated heparin 60 IU/kg bolus (max. 4000 IU) 12 IU/kg/hr infusion (max 1000 IU/ hr) target aPTT 50-70 sec Patients’ outcome will be compared with matched pairs extracted from the corresponding arm of the ASSENT-3 main study. The same exploratory endpoints (single and composite) as in the ASSENT-3 main study will be evaluated; the influence of time to treatment will be analyzed. (500) TNK-tPA full dose 0.53 mg/kg bolus Enoxaparin 30 mg i.v. bolus 1 mg/kg s.c. twice a day (500)
  • 14. Hours to treatment (median) 3+ 0 12 24 36 48 60 72 84 96 108 120 132 144 156 168 ENOX UFH TNK TNK Symptom - call Call - arrival Arrival - Rand. Rand. - first drug First drug - ER ASSENT-3 In-hospital Symptom – TNK 45 min
  • 15. Thrombolysis or PTCA still a debate ?
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21. DANAMI-2 DENMARK 5.4 mill. inhabitants 5 PCI centers 24 referral hospitals 62% of Danish population Transport distance up to 95 US miles (mean 35 miles) 100 US miles
  • 22.
  • 23.
  • 24.
  • 25. Preventing Reinfarction : IIb/IIIa Inhibitors, Enoxaparin, or Primary PCI PRAGUE-2 30-day deaths 6.8 v 10.0 % , p = 0.12 * 6-month data in press, Simes AHU 2002 ** Pre-hospital administration p < 0.05 reMI, death (PCAT only) ; stroke (PCAT only) CAPTIM 840 PCI t - PA** DANAMI - 2 1.572 PCI t - PA C - PORT* 451 PCI t - PA PCAT* 2.725 PCI lytic Death 4.6% 3.7% 6.6% 7.6% 6.2% 7.1% 6.2% 8.2% ReMI 1.7% 3.7% 1.6% 6.3% 5.3% 10.6% 4.8% 9.8% Stoke 0 1.0% 1.1% 2.0% 2.2% 4.0% 0.7% 1.9%
  • 26. DANAMI-2 vs CAPTIM vs ASSENT-3 Mortality at 30 days % (TNK + ENOX) ESSAI TOTAL 6.6 4.8 7.6 3.8 5.4 5.8 0 2 4 6 8 DANAMI-2 CAPTIM ASSENT-3 ASSENT3+ PCI TT
  • 27. CAPTIM 1-Year Results Pre-Hospital Lysis Primary PCI Death GW Symposium, AHA 2002 Death Pre-Hospital Lysis Primary PCI Sx < 2 hours Sx > 2 hours P=0.057 P=0.47 2.2% 5.7% 0% 5% 5.9% 3.7% 0% 10%
  • 28. CAPTIM 1 Year Results Pre-Hospital Lysis Primary PCI P=0.032 Shock Randomization to DC GW Symposium, AHA 2002 P=0.0007 Shock Randomization to Adm Pre-Hospital Lysis Primary PCI Sx < 2 hours Sx < 2 hours 1.3% 5.3% 0% 5% 0.0% 3.6% 0%
  • 29. All presented periods are median Beginning of pain 65 min Emergency call at SAMU 19 min PEC SMUR Beginning of thrombolysis 35 min 66 min Arrival at hospital 84 min Puncture According to ATLS: 32 min 120 min 185 min E-MUST Comparable periods
  • 30.  
  • 31. The Lille Experience 4h55 3h 3h 1h49 1h42 0 1 2 3 4 5 6 Thr. pre-hosp. Thr. pre-hosp. + angioplasty Thr. hosp. Thr. hosp.+ angioplasty Angioplasty
  • 32.
  • 33. One-month Mortality in Patients with Reperfusion Therapy: USIC 2000 n = 428 370 108 47 % 41 % 12 % 7.9 7.8 4.6 0 1 2 3 4 5 6 7 8 9 Primary PTCA IV lysis Lysis + PTCA
  • 34. USIC 2000: One-month Mortality in Patients with Reperfusion Therapy n = 370 108 428 41% 12% 47% 7.1 9.6 3.0 5.8 3.6 7.9 0 2 4 6 8 10 12 Hosp. lysis no PCI Pre-hosp. lysis no PCI Hosp. lysis + PCI Pre-hosp. lysis + PCI Primary PCI
  • 35. Combined Strategy of reperfusion
  • 36. The Combined Strategies of Reperfusion J.M. Julliard : A matched comparison of the combination of prehospital thrombolysis and stand bye rescue angioplasty with primary angioplasty. Am.J. Cardiol. 1999 ; 83 - 305-310. 170 patients in Paris city Pre-hospital Thrombolysis Angiography at 80 min TIMI 3 108 (64%) TIMI 2 12 (7%) TIMI 0 50 (29%) angioplasty TIMI 3 91% TIMI 2 7%
  • 37.
  • 38.
  • 39. 131 patients Angiography 95 min after TT 64 (49%) TIMI 3 54 (84%) PTCA 65 (50%) TIMI 0 - 2 PTCA 119 (91%) PTCA 114 stent 120/131 TIMI 3 (92%) 9/131 TIMI 2 2 TIMI 0-1 no emergency surgery From C. Loubeyre
  • 40.
  • 41. Early PCI versus Guided PCI after Lytics in the Modern Era Death Relative risk, fixed model Bilateral CI, 95% for trials, 95% for MA SIAM III 0.44 [0.14;1.37] GRACIA-1 0.57 [0.26;1.26] CAPITAL-AMI 0.67 [0.11;3.89] Total 0.54 [0.29;0.99] 0.047 Cochran Q het. p=0.91 Rel. Risk 0 1 2 3 4 0.538, p=0.047 RR CI p
  • 42. Rescue PCI after Lytics RESCUE 0.53 [0.16;1.75] REACT 0.51 [0.24;1.10] MERLIN 1.14 [0.59;2.20] LIMI 0.84 [0.27;2.65] Belenkie et al 0.19 [0.02;1.47] Total 0.73 [0.48;1.11] 0.138 Cochran Q het. P=0.33 Death 6 weeks Relative risk, fixed model Bilateral CI, 95% for trials, 95% for MA Rel. Risk 0.4 1.0 1.6 2.2 RR CI p
  • 43.
  • 44.